Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous LSC and CSSC Co-transplantation for LSCD
NCT06700655Phase 2Not yet recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, open-label trial in limbal stem cell deficiency (LSCD) (3 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Vision at 2 years. Planned start Dec 2024; status: not yet recruiting.
02
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on NCT06700655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06700655.